March 22, 2013 at 14:51 PM EDT
Johnson & Johnson's Quest to Knock Botox off the Pedestal
A recent report showed the holding company, Johnson & Johnson (NYSE: JNJ ) seeking FDA approval next year for an anti-wrinkle drug that could dramatically push down Allergan's (NYSE: AGN ) Botox from its 85 percent market share. David Wilson, president of J&J's Mentor division is confident
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here